Loading market dashboard
Novavax, Inc.
NVAXHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Novavax (NVAX) reported earnings 30 days ago. What's next for the stock?
Novavax, Inc. (NVAX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
GAITHERSBURG, Md., June 1, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will participate in the 2026 Jefferies Global Healthcare Conference.
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Novavax, Inc. (NVAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
The hantavirus isn't as contagious as the coronavirus, making a global pandemic unlikely. Picking the potential winners in the hantavirus vaccine market would hardly be worth the time and risk.
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up roughly 6% in Monday morning trading, changing hands near $57.52 after Friday's close of $54.35.
Moderna Inc. (NASDAQ:MRNA) and Novavax Inc. (NASDAQ:NVAX) shares moved higher Monday as traders piled back into vaccine names following renewed concerns over a hantavirus outbreak tied to the MV Hondius cruise ship.
Several pharmaceutical stocks are rising in premarket trading in the wake of a hantavirus outbreak. Moderna, Inovio, Novavax, and Emergent Biosolutions rose in early market trading.
Novavax Inc. (NASDAQ:NVAX) stock is trading higher on Friday in reaction to a surge in Moderna Inc. (NASDAQ:MRNA).
GAITHERSBURG, Md., May 7, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the BofA Securities 2026 Health Care Conference.
Novavax's shares rise 16% after Q1 earnings beat estimates as the company expands Matrix-M partnerships across oncology and infectious diseases.
Novavax Inc. (NASDAQ:NVAX) shares are trading higher on Wednesday after the company reported better-than-expected first-quarter financial results.
Novavax, Inc. (NVAX) Q1 2026 Earnings Call Transcript
Novavax (NVAX) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to earnings of $2.93 per share a year ago.
Total revenue of $140 million in the first quarter of 2026 Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M ® in two infectious disease areas In April, Novavax signed a new MTA with a top 10 leading pharmaceutical company and leader in oncology to explore Matrix-M in multiple oncology and infectious disease targets In April, Novavax expanded an existing partnership with a new MTA, providing access to Matrix-M for exploration in up to nine additional identified infectious diseases In February, Novavax expanded an existing MTA with a major global pharmaceutical company to explore an additional field and signed a new MTA with an oncology company Sanofi announced positive results from the Phase 4 COMPARE study, a head-to-head study comparing Nuvaxovid™ and Moderna's mNEXSPIKE that reinforces Nuvaxovid's well established and differentiated reactogenicity profile Novavax's C. difficile vaccine candidate prioritized with potential to enter the clinic as early as 2027 Reiterates 2026 Revenue Framework and Combined R&D and SG&A expense guidance GAITHERSBURG, Md.
Novavax (NVAX) concluded the recent trading session at $8.01, signifying a +1.01% move from its prior day's close.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Kura Oncology (KURA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GAITHERSBURG, Md., April 29, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2026 financial results and operational highlights at 8:30 a.m.
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novavax (NVAX) concluded the recent trading session at $8.84, signifying a +2.31% move from its prior day's close.
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Shares of Novavax, Inc. (NASDAQ: NVAX - Get Free Report) have received an average rating of "Hold" from the ten ratings firms that are covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and five have given a buy recommendation to the company.
In the latest trading session, Novavax (NVAX) closed at $8.53, marking a +1.31% move from the previous day.
The investor, which holds roughly 9% of the company, argued that leadership has failed to translate Novavax's vaccine platform into meaningful commercial success.
Activist investor Shah Capital plans to vote against the re-election of board nominees and the executive compensation package at Novavax's upcoming annual meeting, renewing pressure for changes at the vaccine maker.
Novavax, Inc. (NASDAQ: NVAX - Get Free Report) saw some unusual options trading on Monday. Stock investors purchased 21,020 call options on the stock. This is an increase of approximately 71% compared to the typical daily volume of 12,273 call options. Institutional Trading of Novavax A number of large investors have recently added to or reduced
In the closing of the recent trading day, Novavax (NVAX) stood at $8.02, denoting a -1.47% move from the preceding trading day.
Novavax, Inc. (NASDAQ: NVAX - Get Free Report) crossed above its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $8.28 and traded as high as $8.42. Novavax shares last traded at $8.09, with a volume of 4,148,236 shares trading hands. Analyst Upgrades and Downgrades
The COVID-19 vaccine boom made fortunes almost overnight—and destroyed them just as fast.
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Robert Walker, MD, brings more than 30 years in drug and vaccine development and, most recently, served as Novavax's Chief Medical Officer Dr. Walker will continue advancing Novavax's R&D efforts with a focus on data generation to facilitate partnering discussions, Matrix adjuvant innovation and advancement of the Company pipeline GAITHERSBURG, Md., March 30, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced the appointment of Dr. Robert Walker, MD, as Executive Vice President and Head of Research & Development (R&D).
In the most recent trading session, Novavax (NVAX) closed at $8.95, indicating a -4.18% shift from the previous trading day.
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
The first severe case of the virus has been detected in New York.
Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Novavax, Inc. (NVAX) Presents at Leerink Global Healthcare Conference 2026 Transcript
